No definition available.
Waldenstrom macroglobulinemia, lyphoplasmocytic lymphoma
C3_MACROGLOBULINEMIA_EXALLC
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
Extra metadata
Similar endpoints
↥List of similar endpoints to
Waldenstrom macroglobulinemia, lyphoplasmocytic lymphoma
based on the number of shared cases.
Similar with more cases:
- Waldenstrom macroglobulinemia, lymphoplasmacytic lymphoma
- Malignant neoplasm
- Malignant neoplasm
- Any event in cancer register
- Malignant neoplasm, wide definition for exclusion
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
Key figures
All | Female | Male | |
---|---|---|---|
Number of individuals | |||
Whole population | 945 | 400 | 536 |
Only index persons | 690 | 285 | 405 |
Unadjusted period prevalence (%) | |||
Whole population | 0.01 | 0.01 | 0.01 |
Only index persons | 0.01 | 0.01 | 0.02 |
Median age at first event (years) | |||
Whole population | 71.41 | 71.63 | 71.27 |
Only index persons | 70.58 | 70.73 | 70.47 |
-FinnGen-
Key figures
All | Female | Male | |
---|---|---|---|
Number of individuals | 120 | 52 | 68 |
Unadjusted period prevalence (%) | 0.03 | 0.02 | 0.03 |
Median age at first event (years) | 69.72 | 67.11 | 71.72 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
Mortality – FinRegistry
↥Association
Association between endpoint C3_MACROGLOBULINEMIA_EXALLC and mortality.
Females
Parameter | HR [95% CI] | p-value |
---|---|---|
C3_MACROGLOBULINEMIA_EXALLC | 2.649 [1.88, 3.74] | < 0.001 |
Birth year | 0.995 [0.99, 1.0] | 0.222 |
During the follow-up period (1.1.1998 — 31.12.2019), 134 out of 278 females with C3_MACROGLOBULINEMIA_EXALLC died.
Males
Parameter | HR [95% CI] | p-value |
---|---|---|
C3_MACROGLOBULINEMIA_EXALLC | 2.186 [1.62, 2.94] | < 0.001 |
Birth year | 0.986 [0.98, 1.0] | 0.006 |
During the follow-up period (1.1.1998 — 31.12.2019), 170 out of 371 males with C3_MACROGLOBULINEMIA_EXALLC died.
Mortality risk
Mortality risk for people of age
years, who have C3_MACROGLOBULINEMIA_EXALLC.N-year risk | Females | Males |
---|---|---|
1 | 0.247% | 0.478% |
5 | 1.695% | 2.558% |
10 | 3.791% | 6.208% |
15 | 6.631% | 11.65% |
20 | 12.179% | 19.538% |
Relationships between endpoints
↥Index endpoint: C3_MACROGLOBULINEMIA_EXALLC – Waldenstrom macroglobulinemia, lyphoplasmocytic lymphoma
GWS hits: 1